About this trial
Children with blunt abdominal trauma often get a CT as the first line imaging to evaluate for intra-abdominal organ injury. CT scans have some downsides with regard to radiation exposure, costs, and need for transport. Contrast enhanced ultrasonography has recently shown some promise as a way to detect intra-abdominal organ injury and may be able to replace the need for conventional CT scanning, without the need for ionizing radiation and the ability to be performed at the bedside.
Eligibility criteria
Qualifiers
Hemodynamically stable (defined as not needing massive transfusion protocol and not undergoing an emergent surgical procedure within the next hour)
History of or suspicion for blunt abdominal trauma
Abdominal CT ordered or obtained
Disqualifiers
History of allergic reaction to Lumason, sulfur hexaflouride, sulfur hexafluoride lipid microsphere components, or other ingredients in Lumason (polyethylene glycol, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na), palmitic acid)
Co-existing penetrating abdominal trauma
Known congenital or acquired heart disease
Trial design
Treatments tested in this trial
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]
- contrast-enhanced ultrasound
Treatment groups
Sponsors and collaborators
Children's Hospital of Philadelphia
Lead sponsor
Mayo Clinic
Collaborator